Roberto Labianca
Impact in
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Internal Medicine top 0.2%
- Venous Thromboembolism Diagnosis and Management
Papers in
- Oncology 211
- Colorectal Cancer Treatments and Studies 141
- Colorectal Cancer Surgical Treatments 57
- Pancreatic and Hepatic Oncology Research 27
- Inflammatory Biomarkers in Disease Prognosis 8
-
- Venous Thromboembolism Diagnosis and Management 24
- Co-authors
- Giordano Domenico Beretta (42 shared papers)Daniel J. Sargent (16 shared papers)Bernard Nordlinger (7 shared papers)Stefano Cascinu (54 shared papers)Valter Torri (22 shared papers)Mario Mandalà (22 shared papers)Sandro Barni (54 shared papers)Stefania Mosconi (21 shared papers)
- Journals
- Annals of Oncology (82 papers)Journal of Clinical Oncology (31 papers)European Journal of Cancer (27 papers)British Journal of Cancer (18 papers)Critical Reviews in Oncology/Hematology (11 papers)
- Partner nations
- ItalyFranceUnited States
In The Last Decade
Roberto Labianca
356 papers receiving 31.6k citations
Roberto Labianca's Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 18.1k
- Internal Medicine 1.3k
- Pathology and Forensic Medicine 2.5k
- Geriatrics and Gerontology 428
- Cancer Research 1.6k
Countries citing papers authored by Roberto Labianca
This map shows the geographic impact of Roberto Labianca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Labianca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Labianca more than expected).
Fields of papers citing papers by Roberto Labianca
This network shows the impact of papers produced by Roberto Labianca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Labianca. The network helps show where Roberto Labianca may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Labianca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 372 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Hit paper breakdown → | 2016 | 2685 |
| 2 | Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer Hit paper breakdown → | 2010 | 1292 |
| 3 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Hit paper breakdown → | 2012 | 1231 |
| 4 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 1216 |
| 5 | Randomized Controlled Trial Hit paper breakdown → | 2009 | 1148 |
| 6 | Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Hit paper breakdown → | 2009 | 992 |
| 7 | Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2020 | 947 |
| 8 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Hit paper breakdown → | 1998 | 847 |
| 9 | Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? Hit paper breakdown → | 2004 | 818 |
| 10 | Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial Hit paper breakdown → | 2005 | 817 |
| 11 | 2001 | 774 | |
| 12 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer Hit paper breakdown → | 2018 | 757 |
| 13 | 2005 | 596 | |
| 14 | 2009 | 536 | |
| 15 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Hit paper breakdown → | 2009 | 500 |
| 16 | 2008 | 466 | |
| 17 | DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy Hit paper breakdown → | 2011 | 453 |
| 18 | 2007 | 422 | |
| 19 | 2014 | 416 | |
| 20 | Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Hit paper breakdown → | 2013 | 413 |
About Roberto Labianca
Roberto Labianca is a scholar working on Oncology, Internal Medicine, Pulmonary and Respiratory Medicine, Cancer Research and Anesthesiology and Pain Medicine, having authored 372 papers that have together received 32.8k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (141 papers), Colorectal Cancer Surgical Treatments (57 papers), Gastric Cancer Management and Outcomes (31 papers), Pancreatic and Hepatic Oncology Research (27 papers), Venous Thromboembolism Diagnosis and Management (24 papers), Breast Cancer Treatment Studies (14 papers), Pain Management and Opioid Use (10 papers) and Inflammatory Biomarkers in Disease Prognosis (8 papers). The work is most often cited by research in Oncology (18.1k citations), Internal Medicine (1.3k citations), Pathology and Forensic Medicine (2.5k citations), Geriatrics and Gerontology (428 citations) and Cancer Research (1.6k citations). Roberto Labianca has collaborated with scholars based in Italy, France and United States. Frequent co-authors include Giordano Domenico Beretta, Daniel J. Sargent, Bernard Nordlinger, Stefano Cascinu, Valter Torri, Mario Mandalà, Sandro Barni, Stefania Mosconi, Eric Van Cutsem and Alberto Zaniboni. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer and Critical Reviews in Oncology/Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.